This week's roundup of Houston innovators includes Carlos Estrada of BioWell, Elizabeth Gore of Hello Alice, and Daniel Barvin of Coya Therapeutics. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a podcast with the leader of a new bioindustrial accelerator, a fintech leader celebrating a big win, and an operations expert fighting for an ALS cure.

Carlos Estrada, head of Venture Acceleration at BioWell

Carlos Estrada, head of Venture Acceleration at BioWell, joins the Houston Innovators Podcast to share why Houston is already a great hub for bioindustrial innovation. Photo courtesy of BioWell

Bioindustrial technologies have a high potential for impacting sustainability — but they tend to need a little bit more help navigating the startup valley of death. That's where the BioWell comes in.

Carlos Estrada, head of Venture Acceleration at BioWell, says the idea for the accelerator was came to First Bight Ventures, a Houston-based biomanufacturing investment firm, as it began building its portfolio of promising companies.

"While we were looking at various companies, we found ourselves finding different needs that these startups have," Estrada says on the Houston Innovators Podcast. "That's how the opportunity for the BioWell came about." Read more.

Elizabeth Gore, co-founder and president of Hello Alice

It's a win for Hello Alice and Elizabeth Gore, co-founder and president (right). Photo courtesy Cayce Clifford/Hello Alice

A Houston fintech company is celebrating the dismissal of a lawsuit from former Trump Administration officials.

Last year, America First Legal sued Houston-based Hello Alice and its partner, Progressive Insurance, alleging that their program to award 10 $25,000 grants to Black-owned small businesses constitutes racial discrimination. AFL was founded by former Trump Administration adviser Stephen Miller and features a handful of other former White House officials on its board.

The case has been dismissed by a federal judge in Ohio, who said that the “Plaintiffs fail to allege any injury in fact that would support their standing to seek either retrospective or prospective relief," according to a news release from Hello Alice.

“This resolution marks a pivotal moment not only for our company but for the broader small business community in the United States,” Elizabeth Gore, co-founder and president of Hello Alice, says in the release. “Facing a labor shortage, heightened interest rates, and inflation, this country needs its small business owners, and they, in return, need the capital and resources that programs like Hello Alice provide." Read more.

Daniel Barvin, vice president of operations and patient advocacy at Coya Therapeutics

Daniel Barvin has a neurodegenerative disease in his near future. He joined Houston-based Coya Therapeutics to help fight for a cure to the aggressively deadly ALS. Photo courtesy

When genetic testing proved to Daniel Barvin that he, like his grandfather, aunt, uncle, and father before him, would most likely die of amyotrophic lateral sclerosis, more commonly known as ALS, and/or frontotemporal degeneration (FTD) in his 40s, he didn't slow him down.

in a guest column for InnovationMap, he writes "instead I chose to fight for every chance to change not only my life, but the lives of millions who are suffering or may one day suffer from neurodegenerative disease."

He joined Houston-based Coya Therapeutics in 2021 to support operations and patient advocacy at a company actively developing a therapeutic that can fight neurodegenerative diseases like ALS. Read more.

Daniel Barvin has a neurodegenerative disease in his near future. He joined Houston-based Coya Therapeutics to help fight for a cure to the aggressively deadly ALS. Photo via Getty Images

How this Houston innovator is using his personal connection to ALS fuel his fight for a cure

guest column

We can never predict how our lives will turn out, but then maybe some of us can. Genetic testing showed that I, like my grandfather, aunt, uncle and father before me, would most likely die of amyotrophic lateral sclerosis, more commonly known as ALS, and/or frontotemporal degeneration (FTD) in my 40s.

Being 36, it’s possible that fear could have overtaken my life, but instead I chose to fight for every chance to change not only my life, but the lives of millions who are suffering or may one day suffer from neurodegenerative disease.

ALS is a rare disease that robs one of their ability to control their muscles, leading them to lose their ability to walk, talk and eventually breathe. Eighty percent of cases are sporadic (of unknown origin) and 20 percent have known genetic causes.

When I learned that I carried the C9ORF72 genetic variant, a causative genetic variant for ALS/FTD) my first instincts were to help others understand their status and where they could turn for help. I saw a vacuum for resources and understanding in the genetic ALS space and I knew that thousands were suffering in darkness.

Through the efforts of many, we created the first ever nonprofit – Genetic ALS & FTD: End the Legacy – focused on fighting for the genetic ALS and FTD communities. After making great strides to fight for our rights and access to care, I was asked if I could help my current CEO, Howard Berman, commercialize Dr. Stanley Appel’s regulatory T Cell (Treg) therapy for ALS.

I joined Coya Therapeutics in 2021 as the first employee, working to build a company that would one day bring life changing therapies to patients. Coya’s therapies are based on Dr. Appel’s discovery that neurodegenerative diseases drive an inflammatory response. As inflammation rises, it damages regulatory T cells, and when Tregs are damaged, inflammation becomes a persistent condition driving degeneration and eventually death.

It was at that point that my life changed from the advocacy world to the therapeutic world. Now over three years later, we are closer than ever to making a paradigm change for how patients with ALS and other neurodegenerative diseases are treated.

At Coya, we believe that combination biologics are the future of treating neurodegenerative diseases. COYA 302 is our lead asset, which has shown promising results in a proof-of-concept study released in March of 2023. We are currently working towards a double-blind, placebo-controlled trial for COYA 302 in ALS set to kick off later this year.

I never wanted to live a life so damned by disease, but when put between a rock and a hard place, the only choice is to fight. I don’t know how my life will end, but I hope that my children will know that I faced a great challenge head on with pride and resilience.

In the end, it is the combination of both the worlds I work in that lead to better outcomes for patients, raising awareness and lifesaving research. This ALS Awareness Month, please join us and our partners like the ALS Association, End the Legacy, and I AM ALS in raising awareness about these conditions, their risks, and treatment options.

------

Daniel Barvin is the vice president of operations and patient advocacy at Coya Therapeutics.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Education equity-focused nonprofit taps into robotics, AI to better serve Houston children

the future is bright

Generally, when children are under the age of five, educators believe that they are best suited for and interested in learning, because those are the years in which there is the strongest opportunity to build a broad and solid foundation for lifelong literacy and well-being.

That sentiment is deeply held by Collaborative for Children, the Houston-based nonprofit organization with the mission to meaningfully improve the quality of early childhood education and provide access to cutting-edge technology through its Centers of Excellence to all children, especially those in low-income and marginalized communities.

“The reason the organization was started about 40 years ago is that a group of philanthropists in the greater Houston area suggested that this was so important because 90 percent of the brain develops or grows in the time frame between ages zero to five years of age,” Melanie Johnson, president and CEO of Collaborative for Children, tells InnovationMap.

“And if we were losing children and not preparing them by third grade to be literate, and then subsequently losing them after that for high dropout rates and achievement gaps between poor and affluent children, that this would be the perfect place to start," she continues. "And so, they put the collaborative, the emphasis, and finances collaborative of every, most every early education effort around this region.”

Collaborative for Children’s work in the community is centered around making sure that there is educational equity for all children, regardless of financial status, and providing access to technologies in meaningful ways.

“Ultimately, we want to bridge the digital divide early on so that when children start off their academic journey, they're starting off equipped with the skills to be successful there on,” says Johnson.

Most recently, the institution has focused on utilizing social-emotional learning robots and coding tech toys like the Pepper — the world’s first social humanoid robot able to recognize faces and basic human emotions — and NAO, which resembles human being and stimulates, robots to enhance learning in the classrooms of its Centers of Excellence.

“Technology enhances the learning experience in the Centers of Excellence in ways that a teacher might not be able to,” says Johnson. “Artificial intelligence is used in gamification to allow a child to play and learn while playing.”

For Collaborative for Children, gamification involves transforming typical academic components into gaming themes.

“While playing, the AI gauges the level of skills that they’ve been able to enter into that system and respond with even more challenging tasks or tasks that are still lateral so that they can continue to repeat that skill,” says Johnson.

The socio-emotional learning robots are indeed fascinating, but how does the nonprofit reach these children, and their parents, who might be skeptical of technology?

Ultimately, through the teachers. They draw them in via the technology. If teachers are excited, they act as a conductor of that energy to their students, making their innovative lessons well, electric.

That resonates with most all children, but especially with those diagnosed with autism.

“Robotics like NAO are great for children on the autism spectrum because they are emotionally sensitive and emotionally intelligent,” says Johnson. “They are low sensory, so as NAO runs around the classroom, it can literally have individual and unique conversations with each child based on facial recognition. But most importantly for me, is that this particular robot is able to evaluate children without statistical bias that a teacher might have.

“A teacher might think that because a child confuses the letter D and B, which are basically shaped the same in opposite directions, that they're not learning," she continues. "And the robot will have no prior knowledge in terms of, is this child the better child, or have they been learning throughout the year? The answers are accurate or inaccurate. So, they remove statistical bias when assessing children in the classroom.”

The misconception about teaching technologies is that it’s about screen time. According to Johnson, it’s not. It’s more about interacting with technology.

“We’ve added, you know, all kinds of modern-day technology so that this world that we're preparing these children for 80 percent of the jobs we don't even know will exist when they are adults,” says Johnson. “So, we're just trying to make sure that there is no divide in terms of 21st century skills and 21st century preparation.”

Building Blocks Ep. 12youtu.be

Collaborative for Children has so many facets to assist children with their early development, but there are inherent challenges when attempting to reach their target audience in low-income and marginalized communities that the organization counters with programs like the Collab Lab, which is a mobile classroom that brings critical, future-focused early childhood education directly to the community at no cost.

Collab-Lab is a mobile classroom that brings critical, future-focused early childhood education directly to the community at no cost. Designed to be convenient for families, it connects parents and their youngest children with experts, educators, resources, and proven programs whose goal is to make sure that kids have the skills essential to learning from the moment they walk into kindergarten for the first time.

“There are a myriad of challenges in these communities that we serve, specifically with technology,” says Johnson. “When children enter first grade, and especially second grade, they're given notepads, basically, digital notepads, because it's no good in pre-K oftentimes, but it is very helpful for children who will never have access or have limited access to iPads and things of that nature.

“So while we don't want them to be babysat by screen time and have social media impacting their self-image and self-worth, we definitely want them to have appropriate doses and appropriate uses of technology in the early education, so that those barriers that their parents face with limited means, that these children can go to first grade and into the robotics class and be able to be evaluated and assessed on the digital notepads that are required nowadays,” she continues.

While technology is very important, Collaborative for Children also focuses on the critical social and emotional skills children need as they develop and the all too important relationship between children and their parents and teachers.

“Theory leads our work,” says Johnson. “It's all focused on fine motor skills, gross motor skills, social emotional, can a child build rapport with their teacher and with the students around them. Those things are paramount and will never change.

“What we use technology to do is enhance and remove biases from teacher-pupil interaction, but also to bridge any kind of divide in terms of 21st century skills. And in addition to that, we engage the families. So families who might not know about hydro-fueled cars in those communities that we serve will be able to be exposed to those concepts, as well through our group connections or parent partnerships.”

Ultimately, the last thing Collaborative for Children wants is to send children from early learning and childcare environments into the K-12 system unprepared to be successful for the real world.

“At Collaborative for Children,” adds Johnson. “We are continuously pushing the envelope at our Centers for Excellence so that the children that we serve will always be on the cutting edge.

The last thing Collaborative for Children wants is to send children from early learning and childcare environments into the K-12 system unprepared to be successful for the real world. Photo courtesy of Collaborative for Children

Houston med school develops revolutionary mRNA vaccine for elephants

zoology biology

An innovative team from Baylor College of Medicine and Texas Children’s Hospital has worked with the Houston Zoo to develop a first-of-its-kind treatment for elephants, which has been administered to its first patient.

Tess, the beloved, 40-year-old matriarch of the Houston Zoo’s elephant herd, is recovering well after receiving the first-ever mRNA vaccine against elephant endotheliotropic herpesvirus (EEHV) 1A on Tuesday, June 18. The veterinary staff at the Houston Zoo will monitor Tess in the coming weeks to check her reaction and the efficacy of the vaccine.

EEHV 1A is a deadly infection for Asian Elephants. While generally benign in African Elephants, Asian Elephants can develop fatal hemorrhages. The fatality rate is a whopping 80 percent, making it one of the most serous threats to elephant populations outside of humans.

Anti-viral drugs have some effect on the disease, but two-thirds show no improvement. This has led to a search for a vaccine. For 15 years, the Houston Zoo and Dr. Paul Ling at Baylor College of Medicine’s Department of Virology and Microbiology have partnered to develop the drug. They have been helped by worldwide research from zoos and animal specialists, as well as graduate student Jessica Watts and Dr. Jeroen Pollet at Houston's Texas Children’s Hospital. The research has been funded by private donations, research partnerships, and grants.

Before being inoculated, the mRNA vaccine was exhaustively tested, with the dosage being extrapolated from data involving horses.

Houston Zoo veterinarians will periodically test Tess to see if she is developing the appropriate antibodies. If she is and there are no adverse reactions, the next step will be to administer the vaccine to the rest of the Houston herd. Many of these are Tess’s own children (Tucker, Tupelo, Tilly, and Teddy) and grandchildren (Winnie).

Should the vaccine prove effective, the doses will be made available worldwide to zoos and private elephant sanctuaries. It is likely to have a significant benefit on protecting and preserving the Asian Elephant population. As of January, there are fewer than 50,000 of the animas left in the wild. They are currently listed as endangered, and breeding programs and research done through the Houston Zoo are essential to keeping the animals from going extinct.

------

This article originally ran on CultureMap.

New study says Houston is best city to grow business in

Report

The Bayou City has again received recognition as a top hub for business.

According to a new study by business revenue experts The RevOps Team, Houston is one of the cities in the US with 10 or more companies listed in the S&P 500, and has been named as the number one city with the fastest growing businesses in the U.S. Houston scored the highest Average Business Growth (ABG) at 26.7 percent. The business experts divided the data from the S&P 500 Index to see what businesses had the highest share-price growth in the last year.

Out of the 28 states and the cities with 10 or more businesses listed in the S&P 500, Houston was No. 1t for growing businesses with Atlanta, in second place with 15 companies listed and reaching an ABG of 24.2 percent. Two cities in Texas ranked in the top five with Dallas taking third place at 14.9 percent.

Texas ranked fifth place overall in the top five states for business growth with high-performing businesses like Vistra. Vistra was the company with the highest growth in Texas at 277.68 percent, followed by NRG Energy (NRG) with 170.43 percent and Caterpillar Inc. (CAT) at 69.13 percent.

“You need to be ready to both leverage opportunity and adapt to challenges,” Kerri Linsenbigler of RevOps Team said in a news release. “Growing a business wherever you are in the U.S. is not for the faint-hearted, and business owners in Texas will be proud that they have ranked highly in the top five.”

Earlier this month, over a dozen Houston-based companies madeU.S. News and World Report's collection of the "Best Companies to Work For" in 2024-2025.

In December, the city was ranked among the 25 best metropolitan areas to start a small business in a report by personal finance website The Credit Review placed Houston in the No. 22 spot.